tiprankstipranks
Advertisement
Advertisement

NBIX Stock Latest News

Balanced View on Neurocrine: Vykat XR Safety Overhang, Tempered Ingrezza Growth, and Price Target Raised to $190
RatingsBalanced View on Neurocrine: Vykat XR Safety Overhang, Tempered Ingrezza Growth, and Price Target Raised to $190
2d ago
NBIX
Neurocrine initiates Phase 1 study of NBIP-‘1968
PremiumThe Fly
Neurocrine initiates Phase 1 study of NBIP-‘1968
8d ago
NBIX
Neurocrine price target raised to $194 from $185 at Wedbush
PremiumThe Fly
Neurocrine price target raised to $194 from $185 at Wedbush
12d ago
NBIX
Neurocrine price target raised to $210 from $200 at Canaccord
PremiumThe Fly
Neurocrine price target raised to $210 from $200 at Canaccord
12d ago
NBIX
Neurocrine Biosciences Earnings Call Signals Scaled Growth
PremiumCompany Announcements
Neurocrine Biosciences Earnings Call Signals Scaled Growth
14d ago
NBIX
Neurocrine price target raised to $249 from $246 at Citi
PremiumThe FlyNeurocrine price target raised to $249 from $246 at Citi
15d ago
NBIX
Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating
Premium
Ratings
Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating
15d ago
NBIX
Wells Fargo recommends buying Neurocrine on weakness after solid quarter
Premium
The Fly
Wells Fargo recommends buying Neurocrine on weakness after solid quarter
15d ago
NBIX
Neurocrine price target raised to $196 from $193 at Morgan Stanley
PremiumThe Fly
Neurocrine price target raised to $196 from $193 at Morgan Stanley
15d ago
NBIX
Neurocrine price target raised to $220 from $200 at TD Cowen
PremiumThe Fly
Neurocrine price target raised to $220 from $200 at TD Cowen
15d ago
NBIX
Neurocrine price target raised to $190 from $170 at Deutsche Bank
PremiumThe Fly
Neurocrine price target raised to $190 from $170 at Deutsche Bank
15d ago
NBIX
Neurocrine price target raised to $214 from $199 at BofA
PremiumThe Fly
Neurocrine price target raised to $214 from $199 at BofA
15d ago
NBIX
Neurocrine price target raised to $215 from $210 at Cantor Fitzgerald
PremiumThe FlyNeurocrine price target raised to $215 from $210 at Cantor Fitzgerald
15d ago
NBIX
Neurocrine price target raised to $204 from $200 at Needham
Premium
The Fly
Neurocrine price target raised to $204 from $200 at Needham
15d ago
NBIX
Neurocrine price target raised to $210 from $207 at Piper Sandler
Premium
The Fly
Neurocrine price target raised to $210 from $207 at Piper Sandler
15d ago
NBIX
Neurocrine price target raised to $225 from $186 at Baird
PremiumThe Fly
Neurocrine price target raised to $225 from $186 at Baird
15d ago
NBIX
Neurocrine price target raised to $215 from $188 at Stifel
PremiumThe Fly
Neurocrine price target raised to $215 from $188 at Stifel
15d ago
NBIX
Neurocrine price target raised to $222 from $200 at Guggenheim
PremiumThe Fly
Neurocrine price target raised to $222 from $200 at Guggenheim
15d ago
NBIX
Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating
PremiumRatings
Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating
15d ago
NBIX
Phil Nadeau Raises Neurocrine Price Target to $220 on Exceptional Q2 Beat and Strength Across Ingrezza and Crenessity
PremiumRatingsPhil Nadeau Raises Neurocrine Price Target to $220 on Exceptional Q2 Beat and Strength Across Ingrezza and Crenessity
15d ago
NBIX
Neurocrine reports Q2 adjusted EPS $2.85, consensus $1.98
Premium
The Fly
Neurocrine reports Q2 adjusted EPS $2.85, consensus $1.98
16d ago
NBIX
Neurocrine raises FY26 Ingrezza net sales view to $2.825B-$2.875B
Premium
The Fly
Neurocrine raises FY26 Ingrezza net sales view to $2.825B-$2.875B
16d ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >